Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and...

Descripción completa

Detalles Bibliográficos
Autores principales: Quagliariello, Vincenzo, Passariello, Margherita, Di Mauro, Annabella, Cipullo, Ciro, Paccone, Andrea, Barbieri, Antonio, Palma, Giuseppe, Luciano, Antonio, Buccolo, Simona, Bisceglia, Irma, Canale, Maria Laura, Gallucci, Giuseppina, Inno, Alessandro, De Lorenzo, Claudia, Maurea, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505026/
https://www.ncbi.nlm.nih.gov/pubmed/36158826
http://dx.doi.org/10.3389/fcvm.2022.930797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505026/
https://www.ncbi.nlm.nih.gov/pubmed/36158826
http://dx.doi.org/10.3389/fcvm.2022.930797

Ejemplares similares